Legend Biotech (LEGN) Competitors $34.08 +0.07 (+0.21%) Closing price 04:00 PM EasternExtended Trading$34.53 +0.45 (+1.32%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEGN vs. BNTX, TEVA, GMAB, SMMT, RDY, ASND, VTRS, QGEN, BBIO, and ROIVShould you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Legend Biotech vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma Roivant Sciences BioNTech (NASDAQ:BNTX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Do insiders and institutionals believe in BNTX or LEGN? 15.5% of BioNTech shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is BNTX or LEGN more profitable? BioNTech has a net margin of -12.20% compared to Legend Biotech's net margin of -40.83%. BioNTech's return on equity of -1.84% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Legend Biotech -40.83%-32.00%-20.07% Which has better earnings & valuation, BNTX or LEGN? Legend Biotech has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.88B8.24-$719.92M-$1.60-61.70Legend Biotech$796.84M7.89-$177.03M-$0.88-38.73 Does the media prefer BNTX or LEGN? In the previous week, BioNTech had 6 more articles in the media than Legend Biotech. MarketBeat recorded 8 mentions for BioNTech and 2 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.44 beat BioNTech's score of 0.77 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate BNTX or LEGN? BioNTech presently has a consensus target price of $134.56, indicating a potential upside of 36.31%. Legend Biotech has a consensus target price of $74.22, indicating a potential upside of 117.79%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.79Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Which has more risk & volatility, BNTX or LEGN? BioNTech has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. SummaryBioNTech beats Legend Biotech on 9 of the 16 factors compared between the two stocks. Get Legend Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEGN vs. The Competition Export to ExcelMetricLegend BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.29B$3.16B$5.79B$10.49BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-38.7321.17348.8926.87Price / Sales7.89411.81522.55164.30Price / CashN/A44.8326.0131.15Price / Book5.989.8315.536.50Net Income-$177.03M-$52.82M$3.29B$271.42M7 Day Performance0.59%3.47%200.87%3.69%1 Month Performance-4.16%5.35%184.38%8.07%1 Year Performance-29.78%13.26%325.51%29.65% Legend Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEGNLegend Biotech3.1595 of 5 stars$34.08+0.2%$74.22+117.8%-29.9%$6.29B$796.84M-38.732,609Positive NewsBNTXBioNTech2.6993 of 5 stars$97.88+1.2%$135.80+38.7%-14.3%$23.26B$2.98B-61.176,772Analyst ForecastTEVATeva Pharmaceutical Industries2.8433 of 5 stars$18.90-5.2%$24.71+30.8%+5.0%$22.86B$16.54B-118.1336,830GMABGenmab A/S3.4232 of 5 stars$27.99+0.6%$39.25+40.2%+10.8%$17.85B$3.12B16.272,682SMMTSummit Therapeutics3.1671 of 5 stars$18.94flat$33.79+78.4%-22.6%$14.07B$700K-18.75110RDYDr. Reddy's Laboratories2.687 of 5 stars$14.64-0.2%$16.95+15.8%-5.4%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.9536 of 5 stars$194.62-0.5%$244.36+25.6%+30.7%$11.97B$393.54M-37.721,017Positive NewsVTRSViatris1.1889 of 5 stars$9.60-3.6%$10.40+8.3%-13.1%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQIAGEN4.4429 of 5 stars$45.39+0.2%$49.69+9.5%+5.3%$10.07B$1.98B26.825,765Positive NewsBBIOBridgeBio Pharma4.4028 of 5 stars$51.47+0.5%$63.94+24.2%+95.8%$9.79B$221.90M0.00400ROIVRoivant Sciences3.4326 of 5 stars$13.95-0.9%$17.67+26.6%+25.6%$9.61B$29.05M0.00860Analyst Revision Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives BBIO Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEGN) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
